You can purchase Eylea® from online retailers. Looking for a reliable source offering a good price can be time consuming. But we can help. We have built a vast network of manufacturers and we can help you find the products you are looking for. Our purchasing agents ensure you obtain only authentic products.
DoctorMedica offers free shipping for orders over $250. Thanks to the generous price-matching policy, you can now get genuine products for your spa or medical practice at the lowest price on the market.
Each box contains a single 1ml vial.
A product leaflet is also included in the box.
Thanks to the potent active ingredient it contains, Eylea® is effective in treating:
Eylea® is formulated with 40mg/ml of aflibercept, a strong inhibitor of the placental growth factor (PlGF) and the vascular endothelial growth factor A (VEGF-A) protein.
As well, the formulation contains inactive ingredients such as sodium chloride, polysorbate 20, sucrose, sodium phosphate (monobasic and dibasic monohydrate), and water for injections.
Eylea® (aflibercept) is an anti-VEGF drug capable of binding to the VEGF-A protein, which is associated with the progression of eye diseases, such as myopic CNV or wet AMD. VEGF-A is also linked to the development of swelling in DME, CRVO, and BRVO. Aflibercept is able to exert an inhibitory effect on VEGF, thereby preventing the leakage and growth of ocular blood vessels. At the same time, it prevents the swelling of the retina. As a result, eyesight is dramatically improved.
At the beginning of the treatment, the injection should be performed every month. In terms of injection frequency, after the first five treatments, give Eylea® injection every two months.
The procedure should be carried out under aseptic condition. Prior to the injection, use an eyewash to disinfect the eye. This is to reduce the risk of infection. You may also use an anesthesia to reduce injection-related pain and discomfort. Carry out additional tests after the procedure to avoid complications (Eylea® is known to raise the ocular pressure).
As with most intravitreal injections, the injection may take 15 to 30 minutes to complete.
Eylea® should be used continuously, unless the treatment response is inadequate. Stop the treatment if deemed necessary.
Use Eylea® to treat eye conditions like wet AMD and DME. Use in the treatment of visual impairment in BRVO, CRVO, and myopic CNV.
Formulated using highly potent ingredients, Eylea® is able to deliver long-lasting therapeutic results. The treatments will remain ongoing. For Wet AMD, the Eylea® injection should be repeated monthly (for the first 3 treatments). After that, inject every 2 months. For DME, the treatment is repeated monthly for 5 months, and then given every 2 months. Refer to the product manual for dosing instructions for other conditions.
Eylea® has been scientifically proven to improve eyesight in several eye diseases, such as DME and wet AMD. It also helps to prevent the deterioration of eyesight.
Eylea® is suitable for patients who suffer from visual impairment caused by myopic CNV and macular edema after BRVO/CRVO. The intravitreal injection is also indicated in patients with DME or neovascular AMD.
Common (but mild) side effects include:
The side effects listed above are short-lived, and will eventually resolve themselves.
Eylea® may also cause an allergic reaction.
Your patient should seek medical help if they experience prolonged or severe side effects.
This list of side effects may not be complete. A full list of side effects can be found in the product leaflet. Read the leaflet for more information on contraindications, warnings and precautions.